Arbutus Biopharma (ABUS) Cash & Equivalents (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Cash & Equivalents for 17 consecutive years, with $23.7 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 36.06% year-over-year to $23.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.7 million (down 36.06% YoY) and the FY2025 annual result came in at $18.0 million, down 50.43% from the prior year.
• Cash & Equivalents climbed to $23.7 million in Q1 2026 per ABUS's latest filing, from $18.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ABUS reached as high as $81.3 million in Q1 2022 and fell as low as $17.5 million in Q3 2023.
• A 5-year average of $35.7 million and a median of $31.8 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 71.84% — and 2024, when it soared 130.86%.
• Year by year, Cash & Equivalents stood at $30.8 million in 2022, then fell by 14.59% to $26.3 million in 2023, then surged by 38.22% to $36.3 million in 2024, then slumped by 50.43% to $18.0 million in 2025, then jumped by 31.64% to $23.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $23.7 million, $18.0 million, and $22.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.